Tau-imaging in neurodegeneration
Tau-imaging in neurodegeneration
复制标题
DOI：
10.1016/j.ymeth.2017.08.003
复制
发表时间：
2017-11-01
期刊：
影响因子：
4.8
通讯作者：
Drzezga, Alexander
中科院分区：
文献类型：
--
作者：
Bischof, Gerard N.;Endepols, Heike;Drzezga, Alexander
病理性大脑蛋白质聚集被认为在神经退行性疾病的发展中起着至关重要的作用。例如，蛋白β-淀粉样蛋白以细胞外淀粉样蛋白斑的形式聚集以及蛋白tau以神经元缠结的形式在神经元内沉积代表阿尔茨海默病（AD）的标志。最近，已经引入了用于脑中tau聚集体的体内分子成像的新型示踪剂，补充了用于成像淀粉样蛋白斑块的现有示踪剂。关于这些新示踪剂的可用数据表明，Tau-PET的主题可能相当复杂。一方面，这是指在不同类型的神经退行性疾病中tau病理学的各种形式的出现。另一方面，在不同示踪剂的可比性和标准化、观察到的脱靶/非特异性结合和信号的定量解释方面，仍然需要克服关于这些示踪剂的验证的许多障碍。这些问题必须澄清之前，系统的临床应用，这一令人兴奋的新方法可能成为可能。潜在的应用是指神经变性的早期检测，tau蛋白病和非tau蛋白病之间的鉴别诊断以及治疗试验中的特定患者选择和随访。(C)2017由Elsevier Inc.出版
Pathological cerebral aggregations of proteins are suggested to play a crucial role in the development of neurodegenerative disorders. For example, aggregation of the protein ss-amyloid in form of extracellular amyloid-plaques as well as intraneuronal depositions of the protein tau in form of neurofibrillary tangles represent hallmarks of Alzheimer's disease (AD). Recently, novel tracers for in vivo molecular imaging of tau-aggregates in the brain have been introduced, complementing existing tracers for imaging amyloid-plaques. Available data on these novel tracers indicate that the subject of Tau-PET may be of considerable complexity. On the one hand this refers to the various forms of appearance of tau-pathology in different types of neurodegenerative disorders. On the other hand, a number of hurdles regarding validation of these tracers still need to be overcome with regard to comparability and standardization of the different tracers, observed off-target/non-specific binding and quantitative interpretation of the signal. These issues will have to be clarified before systematic clinical application of this exciting new methodological approach may become possible. Potential applications refer to early detection of neurodegeneration, differential diagnosis between tauopathies and non-tauopathies and specific patient selection and follow-up in therapy trials. (C) 2017 Published by Elsevier Inc.